针对人类免疫缺陷病毒结构蛋白Gag-Pol的抑制剂及其作用机制研究进展

黄国锋,李聪宜,王虹,张文艳

PDF(469 KB)
PDF(469 KB)
吉林大学学报(医学版) ›› 2024, Vol. 50 ›› Issue (4) : 1156-1163. DOI: 10.13481/j.1671-587X.20240432
综述

针对人类免疫缺陷病毒结构蛋白Gag-Pol的抑制剂及其作用机制研究进展

  • 黄国锋,李聪宜,王虹,张文艳()
作者信息 +

Research progress in inhibitors of structural protein Gag-Pol of human immunodeficiency virus and its mechanism

  • Guofeng HUANG,Congyi LI,Hong WANG,Wenyan ZHANG()
Author information +
History +

摘要

Gag-Pol蛋白是人类免疫缺陷病毒(HIV)重要结构蛋白之一,其组成成分包含了HIV的基本骨架蛋白和生命周期中所需要的功能酶,目前以Gag-Pol上不同的功能区为靶点开发的抑制剂包括衣壳(CA)抑制剂、蛋白酶抑制剂、逆转录酶抑制剂和整合酶抑制剂等。CA抑制剂通过抑制CA的成熟或者破坏CA的组装进而影响HIV复制。蛋白酶抑制剂主要的作用机制是抑制蛋白酶对切割位点CA-间隔多肽1(SP1)的切割,逆转录酶抑制剂通过模仿逆转录底物,阻断HIV的逆转录过程,整合酶抑制剂通过靶向整合酶活性中心—锌指结构影响整合酶活性。本文总结了针对HIV Gag-Pol蛋白的抑制剂及其作用机制,并对已批准上市成药的用法用量进行综述,为今后临床联合用药和针对HIV Gag-pol蛋白的新型抑制剂开发提供参考。

Abstract

Gag-Pol protein is one of the important structural proteins of human immunodeficiency virus (HIV), comprising the basic scaffold proteins and functional enzymes required during the lifecycle of HIV. Currently,the inhibitors targeting different functional domains on Gag-Pol include capsid(CA) inhibitors,protease inhibitors, reverse transcriptase inhibitors, and integrase inhibitors. The CA inhibitors inhibit the maturation of CA or disrupt the assembly of CA,so as to affect the replication of HIV. The primary mechanism of protease inhibitors is to inhibit the protease from cleaving at the cleavage site CA-spacer peptide 1(SP1). The reverse transcriptase inhibitors block the reverse transcription process of HIV by mimicking the reverse transcription substrates. The integrase inhibitors impact the activity of integrase by targeting the zinc-finger structure at the active center of integrase. This article summarizes the inhibitors targeting HIV Gag-Pol protein and their mechanisms, and reviews the approved dosages and usages of approved patent drugs,so as to provide the references for the future clinical combination therapies and the development of new inhibitors targeting HIV Gag-Pol protein.

关键词

人类免疫缺陷型病毒 / Gag-Pol蛋白 / 蛋白酶抑制剂 / 逆转录酶抑制剂 / 整合酶抑制剂 / 成熟抑制剂

Key words

Human immunodeficiency virus / Gag-Pol protein / Protease inhibitor / Reverse transcriptase inhibitor / Integrase inhibitor / Maturation inhibitor

中图分类号

R512.91

引用本文

导出引用
黄国锋,李聪宜,王虹,张文艳. 针对人类免疫缺陷病毒结构蛋白Gag-Pol的抑制剂及其作用机制研究进展. 吉林大学学报(医学版). 2024, 50(4): 1156-1163 https://doi.org/10.13481/j.1671-587X.20240432
Guofeng HUANG,Congyi LI,Hong WANG,Wenyan ZHANG. Research progress in inhibitors of structural protein Gag-Pol of human immunodeficiency virus and its mechanism[J]. Journal of Jilin University(Medicine Edition). 2024, 50(4): 1156-1163 https://doi.org/10.13481/j.1671-587X.20240432

参考文献

1 BELL N M, LEVER A M L. HIV Gag polyprotein: processing and early viral particle assembly[J]. Trends Microbiol, 2013, 21(3): 136-144.
2 SUN L, ZHANG X J, XU S J, et al. An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors[J]. Eur J Med Chem, 2021, 217: 113380.
3 SARKAR S, ZADROZNY K K, ZADOROZHNYI R, et al. Structural basis of HIV-1 maturation inhibitor binding and activity[J]. Nat Commun, 2023, 14(1): 1237.
4 GUPTA S, LOUIS J M, TYCKO R. Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles[J]. Proc Natl Acad Sci U S A, 2020, 117(19): 10286-10293.
5 MAMATIS J E, PELLIZZARI-DELANO I E, GALLARDO-FLORES C E, et al. Emerging roles of cyclophilin A in regulating viral cloaking[J]. Front Microbiol, 2022, 13: 828078.
6 BETANCOR G, JIMENEZ-GUARDE?O J M, LYNHAM S, et al. MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation[J]. Nat Microbiol, 2021, 6(8): 1031-1042.
7 MOUHAND A, PASI M, CATALA M, et al. Overview of the nucleic-acid binding properties of the HIV-1 nucleocapsid protein in its different maturation states[J]. Viruses, 2020, 12(10): 1109.
8 RICE W G, TURPIN J A, HUANG M, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein[J]. Nat Med, 1997, 3(3): 341-345.
9 NIKOLAYEVSKIY H, SCERBA M T, DESCHAMPS J R, et al. Reaction kinetics direct a rational synthesis of an HIV-1 inactivator of nucleocapsid protein 7 and provide mechanistic insight into cellular metabolism and antiviral activity[J]. Chemistry, 2018, 24(38): 9485-9489.
10 VAN DOMSELAAR R, NJENDA D T, RAO R, et al. HIV-1 subtype C with PYxE insertion has enhanced binding of gag-p6 to host cell protein ALIX and increased replication fitness[J]. J Virol, 2019, 93(9): e00077-e00019.
11 DEMIROV D G, ONO A, ORENSTEIN J M, et al. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function[J]. Proc Natl Acad Sci U S A, 2002, 99(2): 955-960.
12 QU K, KE Z L, ZILA V, et al. Maturation of the matrix and viral membrane of HIV-1[J]. Science, 2021, 373(6555): 700-704.
13 LIANG G X, ZHAO L, QIAO Y, et al. Membrane metalloprotease TRABD2A restricts HIV-1 progeny production in resting CD4+ T cells by degrading viral Gag polyprotein[J]. Nat Immunol, 2019, 20(6): 711-723.
14 MARZIALI F, CIMARELLI A. Membrane interference against HIV-1 by intrinsic antiviral factors: the case of IFITMs[J]. Cells, 2021, 10(5): 1171.
15 GUZZO C, FOX J C, MIAO H Y, et al. Structural determinants for the selective anti-HIV-1 activity of the all-β alternative conformer of XCL1[J]. J Virol, 2015, 89(17): 9061-9067.
16 KIM J G, SHAN L. Beyond inhibition: a novel strategy of targeting HIV-1 protease to eliminate viral reservoirs[J]. Viruses, 2022, 14(6): 1179.
17 CLAVEL F, MAMMANO F. Role of gag in HIV resistance to protease inhibitors[J]. Viruses, 2010, 2(7): 1411-1426.
18 WENSING A M, VAN MAARSEVEEN N M, NIJHUIS M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance[J]. Antiviral Res, 2010, 85(1): 59-74.
19 CILENTO M E, KIRBY K A, SARAFIANOS S G. Avoiding drug resistance in HIV reverse transcriptase[J]. Chem Rev, 2021, 121(6): 3271-3296.
20 MARIN M, ROSE K M, KOZAK S L, et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation[J]. Nat Med, 2003, 9(11): 1398-1403.
21 BEDWELL G J, ENGELMAN A N. Factors that mold the nuclear landscape of HIV-1 integration[J]. Nucleic Acids Res, 2021, 49(2): 621-635.
22 BUKOVSKY A, G?TTLINGER H. Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease[J]. J Virol, 1996, 70(10): 6820-6825.
23 YAMAMOTO S P, OKAWA K, NAKANO T, et al. Huwe1, a novel cellular interactor of Gag-Pol through integrase binding, negatively influences HIV-1 infectivity[J]. Microbes Infect, 2011, 13(4): 339-349.
24 COSTI R, MéTIFIOT M, CHUNG S, et al. Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase[J]. J Med Chem, 2014, 57(8): 3223-3234.
25 DIXIT U, BHUTORIA S, WU X H, et al. INI1/SMARCB1 Rpt1 domain mimics TAR RNA in binding to integrase to facilitate HIV-1 replication[J]. Nat Commun, 2021, 12(1): 2743.
26 DINH L P, SUN J, GLENN C D, et al. Multi-substituted quinolines as HIV-1 integrase allosteric inhibitors[J]. Viruses, 2022, 14(7): 1466.
27 SCARSI K K, HAVENS J P, PODANY A T, et al. HIV-1 integrase inhibitors: a comparative review of efficacy and safety[J]. Drugs, 2020, 80(16): 1649-1676.
28 DEEKS E D. Elvitegravir: a review of its use in adults with HIV-1 infection[J]. Drugs, 2014, 74(6): 687-697.
29 RHEINEMANN L, DOWNHOUR D M, BREDBENNER K, et al. RetroCHMP3 blocks budding of enveloped viruses without blocking cytokinesis[J]. Cell, 2021, 184(21): 5419-5431.e16.
30 WANG Q K, GAO H B, CLARK K M, et al. CARD8 is an inflammasome sensor for HIV-1 protease activity[J]. Science, 2021, 371(6535): eabe1707.
31 BURDICK R, SMITH J L, CHAIPAN C, et al. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages[J]. J Virol, 2010, 84(19): 10241-10253.
32 MIKL M, PILPEL Y, SEGAL E. High-throughput interrogation of programmed ribosomal frameshifting in human cells[J]. Nat Commun, 2020, 11(1): 3061.
33 KORNIY N, GOYAL A, HOFFMANN M, et al. Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance[J]. Nucleic Acids Res, 2019, 47(10): 5210-5222.
34 WANG X L, XUAN Y F, HAN Y L, et al. Regulation of HIV-1 gag-pol expression by shiftless, an inhibitor of programmed-1 ribosomal frameshifting[J]. Cell, 2019, 176(3): 625-635.e14.
35 ANOKHINA V S, MILLER B L. Targeting ribosomal frameshifting as an antiviral strategy: from HIV-1 to SARS-CoV-2[J]. Acc Chem Res, 2021, 54(17): 3349-3361.
36 CELUM C, MORROW R A, DONNELL D, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial[J]. Ann Intern Med, 2014, 161(1): 11-19.
37 HERNáNDEZ-NOVOA B, MORENO A, PéREZ-ELíAS M J, et al. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)[J]. J Antimicrob Chemother, 2014, 69(2): 471-475.
38 MALDARELLI F. The role of HIV integration in viral persistence: no more whistling past the proviral graveyard[J]. J Clin Invest, 2016, 126(2): 438-447.
39 GUPTA R K, ABDUL-JAWAD S, MCCOY L E, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation[J]. Nature, 2019, 568(7751): 244-248.
40 JIN H L, TANG X R, LI L, et al. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy[J]. Cell Mol Immunol, 2021, 18(3): 660-674.

基金

国家自然科学基金面上项目(82272316);吉林省科技厅分子病毒学重点实验室项目(20102209)

评论

PDF(469 KB)

Accesses

Citation

Detail

段落导航
相关文章

/